{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "regularMarketChangePercent": 16.964289, "regularMarketPrice": 78.6, "exchange": "GER", "shortName": "FORMYCON AG", "longName": "Formycon AG", "messageBoardId": "finmb_84155935", "exchangeTimezoneName": "Europe/Berlin", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "market": "de_market", "marketState": "POST", "esgPopulated": false, "priceEpsCurrentYear": 24.409937, "sharesOutstanding": 15128800, "bookValue": 23.57, "fiftyDayAverage": 70.028, "fiftyDayAverageChange": 8.571999, "fiftyDayAverageChangePercent": 0.12240816, "twoHundredDayAverage": 77.381, "twoHundredDayAverageChange": 1.2190018, "twoHundredDayAverageChangePercent": 0.015753245, "marketCap": 1189123712, "forwardPE": 13.0564785, "priceToBook": 3.3347476, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "averageAnalystRating": "1.5 - Strong Buy", "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1294128000000, "priceHint": 2, "regularMarketChange": 11.400002, "regularMarketTime": 1683905774, "regularMarketDayHigh": 78.7, "regularMarketDayRange": "67.3 - 78.7", "regularMarketDayLow": 67.3, "regularMarketVolume": 58641, "regularMarketPreviousClose": 67.2, "bid": 77.9, "ask": 78.2, "bidSize": 200, "askSize": 280, "fullExchangeName": "XETRA", "financialCurrency": "EUR", "regularMarketOpen": 67.7, "averageDailyVolume3Month": 13312, "averageDailyVolume10Day": 13705, "fiftyTwoWeekLowChange": 16.599998, "fiftyTwoWeekLowChangePercent": 0.26774192, "fiftyTwoWeekRange": "62.0 - 94.1", "fiftyTwoWeekHighChange": -15.5, "fiftyTwoWeekHighChangePercent": -0.16471839, "fiftyTwoWeekLow": 62.0, "fiftyTwoWeekHigh": 94.1, "earningsTimestamp": 1682593140, "earningsTimestampStart": 1687156200, "earningsTimestampEnd": 1687501800, "trailingAnnualDividendRate": 0.0, "trailingPE": 30.34749, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": 2.59, "epsForward": 6.02, "epsCurrentYear": 3.22, "symbol": "FYB.DE"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Fraunhoferstrasse 15", "address2": "Martinsried", "city": "Planegg", "zip": "82152", "country": "Germany", "phone": "49 89 864 667 100", "fax": "49 89 864 667 110", "website": "https://www.formycon.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Formycon AG develops and markets biosimilar products in Germany and Switzerland. It provides FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious retinal diseases, including diabetic macular edema and myopic choroidal neovascularization under the Ranivisio, ONGAVIA, and CIMERLI names. The company's pipeline includes FYB202, a biosimilar candidate for Stelara, a biopharmaceutical used in the treatment of chronic inflammatory diseases, such as moderate to severe psoriasis, as well as for the treatment of Crohn's disease and ulcerative colitis, which has completed the Phase III clinical trial; and FYB203, a biosimilar candidate for Eylea, that treats neovascular age-related macular degeneration and serious retinal diseases that is in Phase III clinical trials. It is also developing FYB206, a biosimilar candidate for Keytruda, for the treatment of cancer; and FYB207, a SARS-CoV-2 blocker, an antiviral drug for the treatment of COVID-19. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.", "fullTimeEmployees": 137, "companyOfficers": [{"maxAge": 1, "name": "Dr. Stefan  Glombitza", "age": 57, "title": "CEO, COO & Member of Exec. Board", "yearBorn": 1965, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Friedrich-Wilhelm  Steinweg", "title": "Co-Founder", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Nicolas  Combe Ph.D.", "title": "Co-Founder", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Enno  Spillner", "age": 52, "title": "CFO & Member of Management Board", "yearBorn": 1970, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Andreas  Seidl", "age": 52, "title": "Chief Scientific Officer & Member of Exec. Board", "yearBorn": 1970, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Nicola  Mikulcik", "age": 51, "title": "Chief Bus. Officer & Member of Exec. Board", "yearBorn": 1971, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Sabrina  Muller", "title": "Sr. Mang. of Corp. Communications & Investor Relations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "maxAge": 86400}}], "error": null}}